Compare PTCT & ABG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | ABG |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 3.8B |
| IPO Year | 2006 | 2001 |
| Metric | PTCT | ABG |
|---|---|---|
| Price | $71.91 | $202.84 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 6 |
| Target Price | $80.65 | ★ $245.17 |
| AVG Volume (30 Days) | ★ 775.1K | 162.3K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.48 | 16.88 |
| EPS | 7.78 | ★ 25.13 |
| Revenue | $264,734,000.00 | ★ $17,999,000,000.00 |
| Revenue This Year | N/A | $5.98 |
| Revenue Next Year | $19.02 | $2.22 |
| P/E Ratio | $9.45 | ★ $8.04 |
| Revenue Growth | ★ 36.19 | 4.71 |
| 52 Week Low | $35.95 | $184.61 |
| 52 Week High | $87.50 | $274.50 |
| Indicator | PTCT | ABG |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 53.49 |
| Support Level | $69.81 | $187.30 |
| Resistance Level | $71.77 | $255.30 |
| Average True Range (ATR) | 2.21 | 5.30 |
| MACD | 0.61 | 2.07 |
| Stochastic Oscillator | 78.34 | 71.41 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Asbury Automotive Group is a regional collection of automobile dealerships that went public in March 2002. The company operates 171 new-vehicle stores and 39 collision centers. Over 70% of new-vehicle revenue is from luxury and import brands. Asbury also offers third-party financing and insurance products and its own F&I products via Total Care Auto. Asbury operates in 15 states (mostly in Rocky Mountain states, Texas, the Northeast, and Southeast). Asbury store brands include Herb Chambers in the Northeast, McDavid and Park Place in Texas, Koons in the Washington, D.C. area, and the Larry H. Miller brand in the Western US. Asbury generated about $18 billion of revenue in 2025 and is based in the Atlanta area. The firm targets at least $30 billion of revenue sometime around 2030.